Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
Lindsey E RoekerChristopher Paul FoxToby A EyreDanielle M BranderJohn N AllanStephen J SchusterChadi NabhanBrian T HillNirav N ShahFrederick LansiganMaryam Sarraf YazdyBruce D ChesonNicole LamannaArun K SingaviCatherine C CoombsPaul M BarrAlan P SkarbnikMazyar ShadmanChaitra S UjjaniHande H TuncerAllison M WinterJoanna M RhodesColleen DorseyHannah MorseCharlene KabelJohn M PagelAnnalynn M WilliamsRyan JacobsAndre GoySivraj MuralikrishnanLaurie PearsonAndrea SitlingerNeil BaileyAnna SchuhAmy A KirkwoodAnthony R MatoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
These data provide insights into current use of venetoclax in clinical practice, including TLS rates observed in clinical practice. We identified opportunities for improved adherence to TLS risk stratification and prophylaxis, which may improve safety.
Keyphrases
- clinical practice
- end stage renal disease
- chronic lymphocytic leukemia
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- prognostic factors
- type diabetes
- machine learning
- skeletal muscle
- metabolic syndrome
- weight loss
- adipose tissue
- artificial intelligence
- insulin resistance
- glycemic control